Neurotech International has moved NTI164 into a registration-enabling Phase III autism trial, but its annual report carries a material going-concern warning. The company says post-year-end debt and equity funding should support the program through topline data, subject to execution and completion.
- Beyond Harmony Phase III trial initiated at Monash Children’s Hospital
- 150 children planned for enrolment in paediatric ASD study
- FY2026 net loss narrowed to $6.54 million
- Cash fell to $2.39 million while operating outflow reached $4.22 million
- Auditor highlighted material uncertainty over the company’s ability to continue as a going concern
Phase III milestone meets funding warning
Neurotech International Limited (ASX:NTI) has reached the most consequential stage of its NTI164 development program, initiating the Beyond Harmony Phase III trial in children with autism spectrum disorder. The progress comes with a harder financial footnote: auditor BDO highlighted a material uncertainty that may cast significant doubt on the company’s ability to continue as a going concern.
The annual report presents both facts as central to the investment case. Neurotech had $2.39 million in cash at 30 June 2026, generated an operating cash outflow of $4.22 million and held net assets of only $611,141. The group’s current liabilities rose to $2.14 million from $285,742 a year earlier, while its net loss narrowed to $6.54 million from $10.60 million.
Beyond Harmony targets 150 children
The Beyond Harmony study received Human Research Ethics Committee approval in February 2026, with the first site activated at Monash Children’s Hospital in March. It is a multi-centre, randomised, double-blind, placebo-controlled trial designed to assess NTI164’s efficacy, safety and tolerability in children with moderate-to-severe, or Level II and III, ASD.
Neurotech plans to enrol 150 patients under an adaptive design. The primary endpoint is change from baseline in the Vineland-3 Adaptive Behaviour Composite score, with Vineland-3 domain scores, SRS-2, CGI-I and CGI-S among the key secondary measures. The company says the trial is intended to generate data that could support potential submissions to Australia’s Therapeutic Goods Administration and the US Food and Drug Administration, not to establish approval itself.
Regulatory package expands beyond autism
NTI164 also gathered regulatory and scientific support in other paediatric neurological indications during the year. The FDA granted Rare Pediatric Disease Designation for Rett Syndrome in October 2025, complementing an existing Orphan Drug Designation. Neurotech also reported peer-reviewed publications covering Rett Syndrome and PANS, alongside a University of Sydney collaboration using human-derived Rett Syndrome neuronal models.
A 90-day GLP repeat-dose toxicity study in beagle dogs found no mortality or dose-limiting toxicities at the highest administered dose of 216 mg/kg/day, which the company says was approximately ten times the highest human dose evaluated in completed studies. These findings strengthen the safety package described in the report, but they do not remove the clinical and regulatory uncertainty attached to later-stage human development.
Post-year-end funding buys development time
Neurotech’s directors say the going-concern assessment rests on further funding, the ability to scale expenditure and potential project-level investment or grants. After year-end, the company entered a $3.15 million secured loan backed by anticipated FY2026 and FY2027 research and development tax offsets, and announced binding commitments for an approximately $4.5 million placement at $0.014 a share.
The report says the placement is intended primarily to fund the Phase III ASD trial, regulatory work and working capital, and is expected to take the company through topline data readout based on its current plan and budget. That expectation remains dependent on completion of the raising, trial execution and the company’s ability to control cash use. During FY2026, Neurotech also received a $4.73 million R&D tax incentive refund, while spending $9.05 million on research and development.
US pathway advances, but no approval is secured
Subsequent to 30 June, the FDA cleared Neurotech’s IND for NTI164, allowing the company to commence its proposed US clinical development program if it elects to do so. The report describes that program as a comprehensive population pharmacokinetic study intended to complement the Australian Phase III trial.
Two US patent applications also received Notices of Allowance covering methods linked to reducing neuroinflammation and treating ASD. The applications are not enforceable patents until formally granted. The next meaningful tests are therefore operational rather than merely documentary: whether recruitment progresses, whether the US pharmacokinetic program begins, and whether available funding lasts until the promised clinical readout.
Bottom Line?
Neurotech has crossed into Phase III, but the value of that milestone now depends on recruitment, cash discipline and whether post-year-end funding converts into enough runway for topline data.
Questions in the middle?
- How quickly will Beyond Harmony enrol its planned 150 children across the expanding site network?
- Will the secured loan and proposed placement provide sufficient funding if recruitment or regulatory work takes longer than planned?
- When will Neurotech decide whether to commence the FDA-cleared US population pharmacokinetic program?